Acetylon begins study of drug candidate for multiple myeloma

09/22/2011 | Mass High Tech (Boston)

Acetylon Pharmaceuticals initiated a Phase I-IIa clinical study of ACY-1215, a drug candidate for relapsed and relapsed-refractory multiple myeloma. Phase I tests the class 2 histone deacetylase inhibitor as a treatment alone and in combination with standard therapies. In Phase IIa, researchers will evaluate the cancer's response to the drug.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY